AllDocs -> cancers

Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity MAL Moneef 1 , BT Sherwood 1,2 , KJ Bowman 1 , RC Kockelbergh 2 , RP Symonds 3 , WP Steward 3 , JK Mellon 2 and GDD Jones * ,1 1 Department of Cancer Studies and Molecular Medicine, Hodgkin Building, University of Leicester, Lancaster Road, PO Box 138, Leicester LE1 9HN, UK; 2 University Division of Urology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK; 3 University Department of Cancer Studies and Molecular Medicine, Osborne Building, Leicester Royal Infirmary, Leicester LE1 5WW, UK In the UK, the two main treatments of invasive bladder cancer are radiotherapy or cystectomy. However, B50% of patients ...

1 [ CANCER RESEARCH 55, 3228-3232, August 1, 1995] Advances in Brief GeIsolin: A Candidate for Suppressor of Human Bladder Cancer Motoyoshi Tanaka, Leonhard Mullauer, Yoshifumi Ogiso, Hisakazu Fujita, Shingo Moriya, Keiji Furuuchi, Tohru Harabayashi, Nobuo Shinohara, Tomohiko Koyanagi, and Noboru Kuzumaki Abstract Human transitional cell carcinomas of the bladder frequently reveal chromosomal abnormalities that span a range between chromosome 9pl2 and 9qter, even at early stages of bladder carcinogenesis. Because the gene that encodes an actin-regulatory protein, gelsolin, is localized in chromosome 9q33, we examined the expression of gelsolin in a number of human bladder cancer cell lines and tissues. In all 6 cell lines and in 14 of the 18 tumor tissues (77.8%), gelsolin expression was undetectable or extremely low in comparison with its expression in normal bladder epithelial cells. ...

Intravesical EOquin (E09) in theTreatment of Superficial Bladder Cancer JAWitjes,AG van der Heijden Dept Urology,UMCN St Radboud,Nijmegen,the Netherlands Gino Lenaz M.D.,Shanta Chawla M.D. Spectrum Pharmaceuticals,Inc.Irvine,CA 92618 Key words:superficial bladder cancer ;intravesical;Eoquin™ EO9 Abstract EOquin and mitomycin-C (frequently used as intravesical agent in superficial bladder cancer ) are structurally similar but the mechanism of action differs with regard to the ability of oxygen to reverse the activation process and elevated levels of reductases in tumor tissue. Why intravesical application of EOquin?: The bladder is a hypoxic region ;there is a presence of DT-diaphorase enzyme in the bladder ;there is no systemic uptake . In an in vitro experiment we used 4 bladder cancer cell lines that were treated for 60 min.with 0-200 µg/mL MMC or EOquin at 37°C or 43°C.Cell ...